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Introduction
Two articles previously published in Breast Cancer
Research provide another example of the political/social/
psychological/scientific quandary presented by regional
cancer clusters [1,2]. A community is concerned by what
it perceives to be its high incidence of cancer, and a
group of activists collaborates with epidemiologists to
investigate the reasons for the cluster. They launch a study
that considers every conceivable cause, but cannot come
up with an answer because of limitations in their study
design.
Findings of the articles
Marin County is a small urban county north of San
Francisco. Its 250,000 predominantly white, non-Hispanic
residents have breast cancer rates approximately 38%
higher than those of the United States as a whole [1]. In
response to concerns about these high rates, breast
cancer activists teamed with cancer epidemiologists to
conduct a case–control study within Marin County.
The paper by Wrensch and colleagues reports the results
of this comparison of personal and environmental risk
factors among 285 breast cancer cases and 286 control
women [1]. The authors found more frequent screening for
breast cancer, and longer and heavier alcohol consump-
tion, among cases compared with controls. They did not,
however, find significant case–control differences with
respect to several other established breast cancer risk
factors, including a family history of the disease and low
parity. Moreover, cases and controls were similar with
respect to age at first residence and to total years of resi-
dence in Marin County. This similarity fails to support expo-
sure to a regional environmental toxicant as an explanation
for the cluster. A limitation of this study is its low power for
detecting case–control differences in risk factors for the
disease, given the homogeneity of the women in the county
with respect to socioeconomic status and its concomi-
tants. A more informative study would have compared the
distribution of established risk factors in Marin County with
those in other California urban counties, to evaluate how
much of the excess might be due to any unfavorable distri-
bution of risk factors in Marin County.
The paper by Clarke and colleagues compares breast
cancer rates and trends in the period 1990–1999 in Marin
County with those in other urban counties in the San
Francisco Bay Area and elsewhere in California [2]. The
investigators found that rates increased more rapidly
during this period in Marin County than in the other coun-
ties. Mortality rates remained constant in Marin County,
while they declined elsewhere. The authors conclude that
these differences are probably explained by Marin Coun-
ty’s unique sociodemographic characteristics. They have
shown that the higher breast cancer rate in Marin County
has persisted for 10 years.
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Abstract
Two articles previously published in Breast Cancer Research illustrate the high rates of breast cancer
in Marin County, a wealthy, urban county immediately northwest of the city of San Francisco. I herein
comment on these articles, and on the political/psychological/scientific dilemma presented by regions
with high cancer rates, such as Marin County. I discuss possible causes for such cancer ‘clusters’, and
conclude with some thoughts about the future.
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The problem
Neither of these studies provides the definitive answer to
the reasons for the cluster for which the breast cancer
activists had hoped [1,2]. State and provincial health
departments are burgeoning with records of similar incon-
clusive attempts to determine the causes of regional
cancer clusters. When the cancer rates in a region show
statistically significant excess compared with rates else-
where, legislators and public health officials feel com-
pelling political and social pressure to respond to the
perceived threat by mandating epidemiological studies.
The apparent breast cancer cluster on Long Island,
which is remarkably similar to that in Marin County, illus-
trates this point. Elevated breast cancer rates in two
Long Island counties prompted breast cancer activists to
lobby for research to uncover the environmental toxi-
cants responsible for the cluster. The outcome was the
Long Island Breast Cancer Study Project, mandated by
the US Congress in 1993. The cornerstone of the Long
Island Breast Cancer Study Project was a 7-year,
$8 million case–control study, the most comprehensive
ever conducted to link breast cancer with environmental
toxicants. The study has produced largely negative
results [3,4]. Its case–control design is suboptimal for its
goals because it cannot evaluate long-term exposures to
the many toxicants having short half-lives in the body.
However, the investigators had little flexibility in choosing
a design because US Congress mandated a
case–control study. The advocates, who previously had
pinned their hopes on this study, now criticize its design
and are lobbying for a congressional Breast Cancer and
Environmental Research Act, which would authorize the
spending of $30 million per year for 5 years for further
research into the relation between breast cancer and
environmental toxicants.
The causes of cancer clusters
What are the reasons for these disturbing and costly clus-
ters? To address this question, it is useful to review the
available data on how much of the breast cancer burden
may be due to established risk factors.
Madigan and colleagues [5] calculated that if every
woman in the United States had the most favorable risk
factor profile (e.g. early age at first childbirth, many chil-
dren), then an estimated 59% of the breast cancer burden
would still remain. (The confidence interval accompanying
this estimate is wide, with anywhere from 20% to 98% of
breast cancer cases remaining after this hypothetical
change to an optimal distribution of risk factors.)
Several studies have evaluated the extent of regional dif-
ferences in US breast cancer rates and have estimated
the fraction of this variation attributable to established risk
factors. Rates generally are lowest in the South, and
highest in the Northeast and in the West [6]. Sturgeon
and colleagues [7] found little difference in regional breast
cancer mortality rates among young women, but larger dif-
ferences among older women. Compared with death rates
in the South, Sturgeon and colleagues noted a 15%
excess in the West and a 30% excess in the Northeast.
Approximately 50% of the excesses in the Northeast and
Midwest, and 10% of the excess in the West, could be
explained by regional differences in established risk
factors. After adjustment for these factors, the magnitude
of excess breast cancer mortality was 13% in the North-
east and West, and 8% in the Midwest.
Robbins and colleagues [8] compared the prevalence of
established risk factors in the San Francisco Bay area
(high incidence) with that of other US areas. They con-
cluded that the elevated incidence in the San Francisco
Bay Area can be explained completely by regional differ-
ences in risk factors. Interestingly, Prehn and West [9]
found rates similar to those in Marin County in California
census block groups with similar socioeconomic charac-
teristics to those in Marin County. Similarly, Laden and col-
leagues [10] found no regional differences in breast
cancer incidence rates among a socioeconomically homo-
geneous cohort of US nurses. The findings suggest that
much of the regional variation may reflect regional variation
in socioeconomic status.
Taken together, these studies suggest that there is inter-
personal variation in incidence and mortality that is not
completely explained by the variation in established risk
factors. In fact, there is increasing evidence [11–13] of
inherited variation in genes affecting breast cancer risk
among women who do not carry mutations of the genes
BRCA1 and BRCA2.
Migrant groups of different ethnicities have settled in dif-
ferent areas of the United States. Because genetic factors
vary with ethnicity, this geographic specificity suggests
that individual genetic variation in risk is distributed non-
randomly across various geographic regions. This risk vari-
ation from one region to another is not taken into account
when testing the null hypothesis that cancer rates in the
given region equal those of other regions. The P values for
rejecting the null hypothesis assume that the incidence
rate for a given age group is uniform for all women in the
age group, regardless of their region of residence. A more
appropriate null hypothesis would specify that the regional
rate (itself an average of the rates of its residents) varies
over regions according to some probability distribution.
Tests of this ‘regional variation null hypothesis’ would
produce fewer statistically significant clusters than do the
existing ‘uniform null hypothesis’ tests. As long as the
uniform null hypothesis is tested, clusters will continue to
appear and continue to alarm the communities in which
they occur.234
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Conclusion and unresolved issues
What is the solution to this dilemma? One solution is to
modify our statistical tests to accommodate the extra-
binomial and extra-Poisson variation in risk from one
geographic region to another. This will reduce the number
of apparent clusters. However, it does not address the
more important question: how can we unravel the reasons
for geographic distribution of individual risk? To do this, we
must understand the sources of interpersonal variation in
cancer risks. Work on this issue is ongoing as cancer epi-
demiologists begin to understand the genetic factors asso-
ciated with risk, and their interaction with the environment.
Meanwhile, the recent episodes in Marin County and Long
Island raise the following critical question: what scientific
evidence would convince breast cancer activists that the
elevated rates in a community are not due to environmen-
tal toxicants? Will they one day conclude that the accumu-
lated epidemiological and molecular evidence does not
support a role for these toxicants, and that precious
resources might better be spent fighting the disease in
other ways? This is not a scientific question, but rather a
social and psychological one. It concerns the level of evi-
dence needed to dislodge an entrenched conviction, one
vested with potent emotional force.
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